DIFFERENTIATION OF POSTPARTUM THYROTOXICOSIS BY SERUM THYROGLOBULIN - USEFULNESS OF A NEW MULTISITE IMMUNORADIOMETRIC ASSAY

被引:18
作者
HIDAKA, Y [1 ]
NISHI, I [1 ]
TAMAKI, H [1 ]
TAKEOKA, K [1 ]
TADA, H [1 ]
MITSUDA, N [1 ]
AMINO, N [1 ]
机构
[1] OSAKA UNIV,SCH MED,DEPT OBSTET & GYNECOL,SUITA,OSAKA 565,JAPAN
关键词
D O I
10.1089/thy.1994.4.275
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Destruction-induced thyrotoxicosis and Graves' thyrotoxicosis must be differentiated, since they are treated differently. To find a useful marker, we examined serial changes in serum thyroglobulin (Tg) concentrations in 20 patients with postpartum thyroid disease (9, euthyroid Hashimoto's disease; 11, Graves' disease in remission in early pregnancy). Serum Tg was measured by a new multisite immunoradiometric assay that allows little influence of anti-Tg autoantibodies. Eight women developed destruction-induced thyrotoxicosis 1 to 4 months postpartum, 6 had relapse of Graves' thyrotoxicosis 2 to 4 months postpartum, and 6 remained euthyroid, In destruction-induced thyrotoxicosis, serum Tg 2 months before the onset was 13.3 +/- 11.4 mu g/L, then clearly increased 1 month before (34.5 +/- 31.9 mu g/L) and was even higher at the onset of thyrotoxicosis (116.5 +/- 137.1 mu g/L). In contrast, serum Tg increased only at the onset in Graves' thyrotoxicosis (from 25.9 +/- 25.2 mu g/L I month before to 76.1 +/- 75.3 mu g/L at the onset,p < 0.05). There was no difference in serum Tg level at the onset between the two disorders. However, when data were expressed as the percent increase from the level one month before, and the cut-off value were taken at 150%, all 7 patients above the cut-off developed destruction-induced thyrotoxicosis, and 6 of 7 below had recurrent Graves' thyrotoxicosis. Thus, serial measurement of serum Tg is useful for the differentiation of destruction-induced thyrotoxicosis from Graves' thyrotoxicosis after delivery.
引用
收藏
页码:275 / 278
页数:4
相关论文
共 13 条
[1]  
AMINO N, 1978, LANCET, V2, P344
[2]  
AMINO N, 1983, AUTOIMMUNE ENDOCRINE, P247
[3]  
AMINO N, 1986, THYROID, P546
[4]  
KATO R, 1987, ENDOCRINOL JAPON, V34, P171
[5]   SERUM THYROGLOBULIN CHANGES IN PATIENTS WITH GRAVES-DISEASE TREATED WITH LONG-TERM ANTI-THYROID DRUG-THERAPY [J].
KAWAMURA, S ;
KISHINO, B ;
TAJIMA, K ;
MASHITA, K ;
TARUI, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (03) :507-512
[6]  
PIECHACZYK M, 1989, CLIN CHEM, V35, P422
[7]  
PREISSNER CM, 1988, CLIN CHEM, V34, P1794
[8]   INVITRO STUDIES OF THE THYROGLOBULIN DEGRADATION PATHWAY - ENDOCYTOSIS AND DELIVERY OF THYROGLOBULIN TO LYSOSOMES, RELEASE OF THYROGLOBULIN CLEAVAGE PRODUCTS - IODOTYROSINES AND IODOTHYRONINES [J].
ROUSSET, B ;
SELMI, S ;
ALQIER, C ;
BOURGEAT, P ;
ORELLE, B ;
AUDEBET, C ;
RABILLOUD, R ;
BERNIERVALENTIN, F ;
MUNARISILEM, Y .
BIOCHIMIE, 1989, 71 (02) :247-262
[9]  
TACHI J, 1989, THYROIDOLOGY, V2, P85
[10]   SERIAL CHANGES IN THYROID-STIMULATING ANTIBODY AND THYROTROPIN BINDING INHIBITOR IMMUNOGLOBULIN AT THE TIME OF POSTPARTUM OCCURRENCE OF THYROTOXICOSIS IN GRAVES-DISEASE [J].
TAMAKI, H ;
AMINO, N ;
AOZASA, M ;
MORI, M ;
TANIZAWA, O ;
MIYAI, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 65 (02) :324-330